Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 5/20 | 0.80 |
| ▸ | GABRA5 | P31644 | 5/20 | 0.80 |
| ▸ | GABRA2 | P47869 | 5/20 | 0.80 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.80 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.80 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.80 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.80 |
| ▸ | HTR2A | P28223 | 1/20 | 0.80 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.80 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.80 |
| ▸ | PTAFR | P25105 | 10/20 | 0.76 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.76 |
| ▸ | TSHR | P16473 | 1/20 | 0.76 |
| ▸ | BRD4 | O60885 | 2/20 | 0.73 |
| ▸ | HPGD | P15428 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | CNR1 | P21554 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triazolam SCHEMBL29228 | 0.89 | GABRA1 (1.00) | GABRA1GABRA5GABRA2GABRA3OPRK1 | |
| Triazolam SCHEMBL5142333 | 0.89 | GABRA1 (1.00) | GABRA1GABRA5GABRA2GABRA3OPRK1 | |
| Triazolam SCHEMBL29382425 | 0.89 | GABRA1 (1.00) | GABRA1GABRA5GABRA2GABRA3OPRK1 | |
| Triazolam SCHEMBL29368430 | 0.89 | GABRA1 (1.00) | GABRA1GABRA5GABRA2GABRA3OPRK1 | |
| Triazolam SCHEMBL29349744 | 0.89 | GABRA1 (1.00) | GABRA1GABRA5GABRA2GABRA3OPRK1 | |
| SCHEMBL13352295 | 0.89 | GABRA1 (0.83) | GABRA1GABRA5GABRA2GABRA3OPRK1 | |
| SCHEMBL11618597 | 0.88 | GABRA1 (0.67) | GABRA1GABRA5GABRA2GABRA3OPRK1 | |
| Triazolam SCHEMBL27600059 | 0.88 | GABRA1 (0.98) | GABRA1GABRA5GABRA2GABRA3OPRK1 | |
| Triazolam SCHEMBL9055695 | 0.88 | GABRA1 (0.98) | GABRA1GABRA5GABRA2GABRA3OPRK1 | |
| SCHEMBL14497013 | 0.87 | GABRA1 (0.79) | GABRA1GABRA5GABRA2GABRA3OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618958-B2 | Convulsant disorders having the side effects of reduced alcohol craving in human alcoholics and a concomitant reduced sedative, hypnosis; Ethyl 8-bromo-6-phenyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-20080108605-A1 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| US-7235656-B2 | Anxiolytic agents with reduced sedative and ataxic effects | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-20070054881-A1 | Orally active benzodiazepine derivatives and their salts; anticonvulsants with reduced hypnotic and muscle relaxant side effects; eating and psychological disorders | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| WO-2006004945-A1 | STEREOSPECIFIC ANXIOLYTIC AND ANTICONVULSANT AGENTS WITH REDUCED MUSCLE-RELAXANT, SEDATIVE-HYPNOTIC AND ATAXIC EFFECTS | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2006-01-12 | — | — | WO | disclosed |
| WO-2003082832-A2 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2003-10-09 | — | — | WO | disclosed |
| US-4018788-A | 6-(O-Halophenyl)-1-methyl-4H-s-triazolo[4,3-a][1,4]-benzodiazepine | THE UPJOHN COMPANY (US) | 1977-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108605-A1 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | GABRA3, GABRA2, GABRA1 | GABRA1 3/4885GABRA5 6/4885GABRA2 2/4885 |
| US-20070054881-A1 | Orally active benzodiazepine derivatives and their salts; anticonvulsants with reduced hypnotic and muscle relaxant side effects; eating and psychological disorders | GABRA3, GABRA6, GABRA4 | GABRA1 5/4885GABRA5 6/4885GABRA2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.